There are no FDA-approved treatments for nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), two chronic and progressive liver diseases. Intermountain is working with several industry partners to evaluate novel treatment regimens in patients with these underlying conditions and ultimately bring them to the market in the United States. Intermountain researchers are also working on ways to identify "at risk" patients in our system and develop new interventions to help providers diagnose these patients before their disease progresses. 

Learn more about the clinical trials